Core Viewpoint - TaiLong Pharmaceutical's stock price increased by 3.24% to 7.00 CNY, reflecting positive market sentiment and trading activity [1] Company Overview - TaiLong Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on three core business segments: drug formulations, traditional Chinese medicine pieces, and pharmaceutical research and development services [1] - The company was established in 1993 and became the first listed pharmaceutical company in Henan Province when it went public on the Shanghai Stock Exchange in 1999 [1] Recent Developments - On August 15, TaiLong Pharmaceutical announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives [1] - The company elected five non-independent directors and three independent directors, with Wang Rongtao being appointed as the chairman of the tenth board of directors [1] - Wang Rongtao has previously held positions as the secretary and chairman of Zhengzhou High-tech Construction Group Co., Ltd., and currently serves as a member of the party branch and vice chairman of Zhengzhou High-tech Science City Investment Development Group Co., Ltd. [1] Stock Performance - The stock opened at 6.73 CNY, reached a high of 7.20 CNY, and a low of 6.64 CNY during the trading session [1] - The trading volume was 548,988 hands, with a total transaction value of 381 million CNY [1]

请发行人说明:(1) 公司一致性评价业务 2019年采用完工百分比法确认收入 的原因,与采用形象进度法确认收入的差异、对经营业绩的具体影响;(2)公司 各项业务设置不同收入确认时点和确认比例的原因及合理性,与行业可比公司是 否一致,各时点收入比例确认的依据,按行业通行的确认时点和确认比例模拟测 算公司收入、成本及利润情况,是否存在显著差异;(3)2020年后,相关节点收 入确认比例显著提高的原因、依据及合理性,是否符合业务开展实际,对经营业 绩的具体影响,是否存在通过变更会计政策调节业绩的情况。 希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司向特定对象发行股票 申请文件的审核问询顾回复 上海证券交易所: 贵所于 2023年3月23日出具的上证上审(再融资)(2023)146号《关于新 疆百花村医药集团股份有限公司向特定对象发行股票申请文件的审核问询函》(以 下简称"问询函")已收悉。根据贵所问询函提出的要求,我们在审慎核查的基础 上,就问询函中的有关问题回复说明如下: 1、根据申报材料,发行人主要以形象进 ...